Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Multi-Perspective Tolerance Evaluation of Bacillus Calmette-Guerin with Interferon in the Treatment of Non-Muscle Invasive Bladder Cancer

Multi-Perspective Tolerance Evaluation of Bacillus Calmette-Guerin with Interferon in the... Background:Bacillus Calmette-Guerin (BCG) toxicities have been reported but with relative agranularity regarding severity and temporal changes during therapy. In its most severe form, BCG intolerance remains poorly understood and exploring ways to optimize toleration of the most effective treatment (BCG) is prudent.Objective:To report the results of both patient- and physician-centered metrics of BCG toxicity as part of the National Phase II BCG/Interferon (IFN) study, as well as the efficacy of low-dose BCG/IFN for previously deemed BCG intolerant patients.Methods:Patients were treated with 6 weekly treatments of BCG (various dosing based on prior BCG exposure) with 50 million units of IFN. BCG intolerance was strictly defined. Maintenance BCG was instituted if disease free. Treatment tolerance during induction was measured using physician- and patient-completed evaluations. Linear mixed effects regression was used to evaluate differences.Results:533 BCG naïve, 415 BCG failure, and 37 BCG intolerant patients were enrolled. There was no significant difference in quality of life scores between groups (p = 0.70). A predictable temporal toxicity pattern was identified in all groups with symptom resolution by day 2-3. Despite BCG intolerant patients having significantly worse bladder pain/spasms and cystitis, treatment discontinuation was under 4%. Recurrence-free survival was similar between naïve and intolerant patients.Conclusions:BCG toxicity is common and follows a predictable pattern. While at slightly increased risk of toxicity, BCG intolerant patients may be managed successfully with 1/10th dose BCG with IFN. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bladder Cancer IOS Press

Multi-Perspective Tolerance Evaluation of Bacillus Calmette-Guerin with Interferon in the Treatment of Non-Muscle Invasive Bladder Cancer

Download PDF
11 pages

Loading next page...
 
/lp/ios-press/multi-perspective-tolerance-evaluation-of-bacillus-calmette-guerin-kpAG5hfEui

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
IOS Press
Copyright
Copyright © 2019 © 2019 – IOS Press and the authors. All rights reserved
ISSN
2352-3727
eISSN
2352-3735
DOI
10.3233/BLC-180203
Publisher site
See Article on Publisher Site

Abstract

Background:Bacillus Calmette-Guerin (BCG) toxicities have been reported but with relative agranularity regarding severity and temporal changes during therapy. In its most severe form, BCG intolerance remains poorly understood and exploring ways to optimize toleration of the most effective treatment (BCG) is prudent.Objective:To report the results of both patient- and physician-centered metrics of BCG toxicity as part of the National Phase II BCG/Interferon (IFN) study, as well as the efficacy of low-dose BCG/IFN for previously deemed BCG intolerant patients.Methods:Patients were treated with 6 weekly treatments of BCG (various dosing based on prior BCG exposure) with 50 million units of IFN. BCG intolerance was strictly defined. Maintenance BCG was instituted if disease free. Treatment tolerance during induction was measured using physician- and patient-completed evaluations. Linear mixed effects regression was used to evaluate differences.Results:533 BCG naïve, 415 BCG failure, and 37 BCG intolerant patients were enrolled. There was no significant difference in quality of life scores between groups (p = 0.70). A predictable temporal toxicity pattern was identified in all groups with symptom resolution by day 2-3. Despite BCG intolerant patients having significantly worse bladder pain/spasms and cystitis, treatment discontinuation was under 4%. Recurrence-free survival was similar between naïve and intolerant patients.Conclusions:BCG toxicity is common and follows a predictable pattern. While at slightly increased risk of toxicity, BCG intolerant patients may be managed successfully with 1/10th dose BCG with IFN.

Journal

Bladder Cancer – IOS Press

Published: Jan 1, 2019

References

  • EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
    Babjuk
  • Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
    Chang
  • Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma
    Brosman
  • A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder
    Lamm
  • Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study
    Lamm
  • Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder
    Sylvester
  • Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials
    Sylvester
  • 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group
    Malmstrom
  • Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
    van der Meijden
  • Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: Results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG
    Brausi
  • Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer
    Lamm
  • The quality of life during intravesical bacillus Calmette-Guerin therapy
    Bohle
  • Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer
    Joudi
  • A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: Low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C
    Ojea
  • Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer
    Martinez-Pineiro
  • Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity
    Luo
  • IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy
    Luo
  • Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer
    Stricker
  • A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder
    Glashan
  • Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group Study
    Torti
  • Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer
    Nepple